Results 1 to 10 of about 1,814 (132)
Biomedicines, 2021 We compared the short-term outcomes between 3-monthly aflibercept and brolucizumab injections for treatment-naïve polypoidal choroidal vasculopathy (PCV). A total of 52 eyes were included.
Kenji Kashiwagi +2 more
exaly +3 more sources
Off-label intravitreal brolucizumab and bevacizumab for chronic central serous chorioretinopathy [PDF]
International Journal of OphthalmologyAIM: To compare the intravitreal brolucizumab and bevacizumab injections for chronic central serous chorioretinopathy (cCSC). METHODS: Patients with cCSC were classified into bevacizumab and brolucizumab group.
Jung Yeon Joo +2 more
doaj +2 more sources
Comparison of Three Consecutive Monthly Administrations Between Aflibercept 8 mg and Brolucizumab 6 mg in Polypoidal Choroidal Vasculopathy [PDF]
PharmaceuticalsPurpose: The aim was to compare the short-term outcomes of aflibercept 8 mg and brolucizumab for the treatment of polypoidal choroidal vasculopathy (PCV). Methods: This study included 48 eyes of 48 patients with PCV.
Yoshiko Fukuda +4 more
doaj +2 more sources
Effectiveness, Safety, and Real-World Experience of Brolucizumab: A Systematic Review [PDF]
PharmaceuticalsBackground/Objectives: Brolucizumab is a humanized single-chain antibody fragment with a molecular weight of approximately 26 kilodaltons (scFv, ~26 kDa) targeting all VEGF-A isoforms.
Naif M. Alali +10 more
doaj +2 more sources
Aflibercept and Brolucizumab in Diabetic Macular Edema: A Focused Review of Efficacy, Safety, and Clinical Considerations [PDF]
BiomedicinesBackground/Objectives: Diabetic macular edema (DME) are major causes of visual impairment worldwide, with vascular endothelial growth factor (VEGF) playing a central role in disease pathogenesis.
Ana Maria Dascalu +9 more
doaj +2 more sources
Current Landscape and Future Perspectives of Diabetic Retinopathy Therapy: Pharmacological Targets, Precision Laser Technology, and Clinical Evidence [PDF]
MedComm, Volume 7, Issue 7, July 2026.Targeted biological agents targeting VEGF, integrin, dopamine D2 receptor, ROCK, and BCL‐XL have entered the clinical trial phase and deserve particular attention. The treatment paradigm has shifted toward personalized and precision medicine, positioning optimized SML as a promising adjunctive therapy.
Xinying Hu +7 more
wiley +2 more sources
American Journal of Ophthalmology Case ReportsPurpose: To compare the safety and efficacy of aflibercept with brolucizumab for recalcitrant diabetic macular edema (DME). Observations: At week 52, no significant visual improvement was noted in the eyes treated with either brolucizumab (P = 0.527) or ...
Debdulal Chakraborty +2 more
exaly +3 more sources
Frontiers in Pharmacology, 2022 Introduction: As demonstrated in pivotal clinical trials, brolucizumab can be used to treat neovascular age-related macular degeneration (nAMD) because it antagonizes vascular endothelial growth factor (VEGF) in the vitreous.
Junlan Chuan +10 more
doaj +1 more source
Choroidal Effusion following Intravitreal Brolucizumab Injection: A Case Report
Case Reports in Ophthalmology, 2022 This report describes a case of choroidal effusion after intravitreal brolucizumab injection for wet age-related macular degeneration (AMD). A 71-year-old Korean man with a history of wet AMD visited our clinic.
Ha Eun Sim, Jae Suk Kim, Je Hyung Hwang
doaj +1 more source
International Journal of Retina and Vitreous, 2023 Background The anti-vascular endothelial growth factor (anti-VEGF) injection interval influences treatment burden and compliance in neovascular age-related macular degeneration (nAMD).
Joseph M. Coney +18 more
doaj +1 more source